Special Issue "Current Flavivirus Research Important for Vaccine Development "
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against (re)emerging and Tropical Infections Diseases".
Deadline for manuscript submissions: closed (31 October 2019) | Viewed by 41840
Special Issue Editors
Interests: antigen specific B cell responses; antibody responses
Special Issue Information
Dear Colleagues,
Climate change, rising populations, and increases in global travel have led to the emergence of a broad array of pathogenic human flavivirus, including Dengue (DENV), Japanese encephalitis (JEV), Rocio (ROCV), Spondweni (SPOV), Tick Borne encephalitis (TBE), Usutu (USUV), West Nile (WNV) yellow fever (YFV), and the Zika (ZIKV) virus. Individually and in combination these viruses are an increasing threat to global health and economic stability with billions of individuals exposed each year.
Vaccinations are one of the most effective interventions to improve public health by reducing infection rate, complications, and death. To establish the scientific foundation for effective vaccine development, several core factors must be defined, including the fundamental mechanisms of disease, correlates of protection, and the natural history of disease. Vaccine approaches then require further adaption for special populations, such as children, the elderly, and the obese. These are the challenges facing virologists and immunologist working toward the development of effective vaccines for flaviviruses.
Dr. James D. Brien
Dr. Amelia K. Pinto
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Flavivirus Animal Model Vaccine Antigen Specific lymphocytes